Document
IPR2018-01714, No. 1055-57 Exhibit - Declaration of James L Mullins, PhD Part 3 of 5 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1055-57 Exhibit - Declaration of James L Mullins, PhD Part 3 of 5 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1025-25 Exhibit - Imashuku et al, Management of severe neutropenia with cyclosporin during initial treatment of Epstein Barr virus related hemophagocytic lymphohistiocyto...
Cite Document
IPR2018-01714, No. 1025-25 Exhibit - Imashuku et al, Management of severe neutropenia with cyclosporin during initial treatment of Epstein Barr virus related hemophagocytic lymphohistiocytosis, Leuk L
+ More Snippets
Document
IPR2018-01714, No. 1004-4 Exhibit - Sampaio et al, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes, J Exp Med, 1733 699 703 1991 (P.T....
Cite Document
IPR2018-01714, No. 1004-4 Exhibit - Sampaio et al, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes, J Exp Med, 1733 699 703 1991 (P.T.A.B. Sep. 12
+ More Snippets
Document
IPR2018-01714, No. 1055-58 Exhibit - Declaration of James L Mullins, PhD Part 4 of 5 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1055-58 Exhibit - Declaration of James L Mullins, PhD Part 4 of 5 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1016-16 Exhibit - Hideshima, et al, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, 962943 2950 200...
Cite Document
IPR2018-01714, No. 1016-16 Exhibit - Hideshima, et al, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, 962943 2950 2000 (P.T.A.B. S
+ More Snippets
Document
IPR2018-01714, No. 1042-42 Exhibit - Morgan J et al, Overall survival with dexamethasone in phase III multiple myeloma trials after adjustment for cross over to lenalidomide, Haematologica 93s...
Cite Document
IPR2018-01714, No. 1042-42 Exhibit - Morgan J et al, Overall survival with dexamethasone in phase III multiple myeloma trials after adjustment for cross over to lenalidomide, Haematologica 93s1, Abstr
+ More Snippets
Document
IPR2018-01714, No. 1041-41 Exhibit - Armoiry, X, et al, Lenalidomide in the treatment of multiple myeloma a review, J Clin Pharm Ther 33219 226 2008 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1041-41 Exhibit - Armoiry, X, et al, Lenalidomide in the treatment of multiple myeloma a review, J Clin Pharm Ther 33219 226 2008 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1009-9 Exhibit - Corral et al, Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF ¿¿, J Im...
Cite Document
IPR2018-01714, No. 1009-9 Exhibit - Corral et al, Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF ¿¿, J Immuno
+ More Snippets
Document
IPR2018-01714, No. 1035-35 Exhibit - J Blade and J Esteve, Treatment Approaches for Relapsing and Refractory Multiple Myeloma, Acta Oncologica, 397843 847 2000 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1035-35 Exhibit - J Blade and J Esteve, Treatment Approaches for Relapsing and Refractory Multiple Myeloma, Acta Oncologica, 397843 847 2000 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1008-8 Exhibit - Muller et al, Amino substituted Thalidomide Analogues Potent Inhibitors of TNF ¿¿ Productions, Bioorganic Medicinal Chemistry Letters, 91625 1630 1999 (P...
Cite Document
IPR2018-01714, No. 1008-8 Exhibit - Muller et al, Amino substituted Thalidomide Analogues Potent Inhibitors of TNF ¿¿ Productions, Bioorganic Medicinal Chemistry Letters, 91625 1630 1999 (P.T.A.B. Se
+ More Snippets
Document
IPR2018-01714, No. 1017-17 Exhibit - V T DeVita, Jr, Chapter 16 Principles of Chemotherapy, Cancer Principles and Practice of Oncology, Fourth Edition 1993 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1017-17 Exhibit - V T DeVita, Jr, Chapter 16 Principles of Chemotherapy, Cancer Principles and Practice of Oncology, Fourth Edition 1993 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1028-28 Exhibit - US Patent No 6,281,230 the 230 Patent (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1028-28 Exhibit - US Patent No 6,281,230 the 230 Patent (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1030-30 Exhibit - Bilgrami et al, Dexamethasone, paclitaxel, etoposide, cyclophosphamide d TEC and G CSF for stem cell mobilisation in multiple myeloma, Bone Marrow Tra...
Cite Document
IPR2018-01714, No. 1030-30 Exhibit - Bilgrami et al, Dexamethasone, paclitaxel, etoposide, cyclophosphamide d TEC and G CSF for stem cell mobilisation in multiple myeloma, Bone Marrow Transplantation,
+ More Snippets
Document
IPR2018-01714, No. 1011-11 Exhibit - Rajkumar Kyle, Thalidomide in the Treatment of Plasma Cell Malignancies, J of Clinical Oncology, 19163593 3595 Aug 2001 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1011-11 Exhibit - Rajkumar Kyle, Thalidomide in the Treatment of Plasma Cell Malignancies, J of Clinical Oncology, 19163593 3595 Aug 2001 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1027-27 Exhibit - Pomalyst Label (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1027-27 Exhibit - Pomalyst Label (P.T.A.B. Sep. 12, 2018)
+ More Snippets